AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|
23.4 C
New York
Thursday, September 17, 2026

Tag: program

newssourceFORcompanyinformationcontent1releasesmarket

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

TSA seeks private sector solutions to enhance airport security and passenger experience

Submissions for Request for Information now open on SAM.gov WASHINGTON, July 25, 2025 /PRNewswire/ -- The Transportation Security Administration (TSA) recently issued a Request for...

Best Kratom? Super Speciosa Relaunches Enhanced Watermelon Kratom Tincture in 2025

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency 
As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

CHICAGO GOURMET 2025 POWERED BY INVESCO QQQ: PREMIER CULINARY FEST, TICKETS ON SALE JULY 25

CHICAGO, July 25, 2025 /PRNewswire/ -- Chicago Gourmet, powered by Invesco QQQ, returns with a sports-themed culinary lineup. Tickets go on sale July 25....

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants 
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

Foreign Investors in Charlotte Eagle Lake (JF42) Project Obtain Conditional Green Card Approval

WASHINGTON, July 25, 2025 (GLOBE NEWSWIRE) -- EB5 Capital is pleased to announce the first individual I-526E petition approval for an investor in its Charlotte Eagle Lake (JF42) project. An I-526E approval is a significant step in the EB-5 immigration process as it qualifies the investor and their eligible family members for conditional permanent residency in the United States. The approved petition was filed in January 2025 and was pending for approximately six months.

Q2 Sales and H1 2025 Financial Results

 

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

GR Silver Mining Extends Silver Mineralization with Step-Out Drilling at San Marcial 11.9 m @ 226 g/t Ag Eq* including 0.9m @ 716 g/t...

VANCOUVER, BC, July 25, 2025 /CNW/ - GR Silver Mining Ltd. ("GR Silver Mining" or the "Company") (TSXV: GRSL) (OTCQB: GRSLF) (FRANKFURT: GPE) – is pleased...

LEARN WHAT THE PTA IS DOING TO HELP OUR NATION’S YOUTH DEVELOP HEALTHY DIGITAL HABITS

PTA CONNECTED INITIATIVE HELPS FAMILIES NAVIGATE RAISING CHILDREN IN THE DIGITAL AGE; PROVIDES FREE TOOLS TO HELP SET HEALTHY LIMITS AND CREATE POSITIVE EXPERIENCES ALEXANDRIA,...

Food Cycle Science Partners with Newfoundland Communities to Revolutionize Food Waste Diversion from Local Landfills

Five rural Newfoundland municipalities adopt FoodCycler® programs to divert food waste from landfills using modern, in-home technology OTTAWA, ON, July 25, 2025 /PRNewswire/ - Newfoundland...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers